Saturday, January 30, 2010 2:19:54 AM
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
Press Release Source: Biotechnology Industry Organization (BIO) Tuesday January 5, 2010, 12:32 pm EST
http://finance.yahoo.com/news/BIO-Announces-Initial-bw-687462266.html?x=0&.v=1
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
* Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
* Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
* Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
* J. Donald deBethizy, Ph.D.; President & CEO, Targacept
* David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
* Howard Furst, M.D.; Partner, Deerfield Management
* Cory W. Kasimov; Vice President , J.P Morgan
* David Kroin; Managing Director, Great Point Partners, LLC
* Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
* Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
* Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
BIO CEO & Investor Conference Bank Sponsors
BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference bank sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Conference Co-Host Rodman & Renshaw, LLC and Supporting Bank Sponsor Lazard.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Recent CVM News
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM